{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:21:33Z","timestamp":1766269293714,"version":"3.37.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose of the Review<\/jats:title>\n                <jats:p>Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Not adequately controlled AH before or during anticancer treatments and\/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-023-00590-5","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T08:02:35Z","timestamp":1674633755000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-152X","authenticated-orcid":false,"given":"Giacomo","family":"Tini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allegra","family":"Battistoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Sarocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Pietrantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domitilla","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"issue":"36","key":"590_CR1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801.","journal-title":"Eur Heart J"},{"key":"590_CR2","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.2459\/JCM.0000000000000381","volume":"17","author":"P Spallarossa","year":"2016","unstructured":"\u2022 Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I, et al. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med. 2016;17:e84. (Physiopathological mechanisms revision and practical recommendations for prevention and management of anthracycline-related cardiotoxicity.)","journal-title":"J Cardiovasc Med"},{"key":"590_CR3","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.2459\/JCM.0000000000000383","volume":"17","author":"N Maurea","year":"2016","unstructured":"\u2022 Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med. 2016;17:e93-104. (Physiopathological mechanisms revision and practical recommendations for prevention and management of anti-VEGF agents-related cardiotoxicity.)","journal-title":"J Cardiovasc Med"},{"key":"590_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3389\/fphar.2020.00972","volume":"11","author":"P Spallarossa","year":"2020","unstructured":"Spallarossa P, Sarocchi M, Tini G, Arboscello E, Toma M, Ameri P, et al. How to monitor cardiac complications of immune checkpoint inhibitor therapy. Front Pharmacol. 2020;11:972.","journal-title":"Front Pharmacol"},{"issue":"1","key":"590_CR5","first-page":"14","volume":"7","author":"T Mohammed","year":"2021","unstructured":"Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardiooncology. 2021;7(1):14.","journal-title":"Cardiooncology"},{"key":"590_CR6","doi-asserted-by":"crossref","unstructured":"\u2022 Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32(7):852\u201362. First review recognizing the multifactorial mechanisms causing cardiotoxicity (inherent drug toxicity, patient's cardiovascular risk profile and genetic predisposition).","DOI":"10.1016\/j.cjca.2015.12.023"},{"key":"590_CR7","doi-asserted-by":"publisher","first-page":"654728","DOI":"10.3389\/fcvm.2021.654728","volume":"8","author":"G Tini","year":"2021","unstructured":"Tini G, Ameri P, Buzzatti G, Sarocchi M, Murialdo R, Guglielmi G, et al. Diversity of cardiologic issues in a contemporary cohort of women with breast cancer. Front Cardiovasc Med. 2021;8:654728.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"590_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11897-018-0400-1","volume":"15","author":"Z Sharalaya","year":"2018","unstructured":"Sharalaya Z, Collier P. Prevention of cardiotoxicities with traditional and novel chemotherapeutic agents. Curr Heart Fail Rep. 2018;15(4):260\u20139.","journal-title":"Curr Heart Fail Rep"},{"issue":"48","key":"590_CR9","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889\u201397.","journal-title":"Eur Heart J"},{"issue":"10","key":"590_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. JCO. 2016;34(10):1122\u201330.","journal-title":"JCO"},{"issue":"26","key":"590_CR11","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1200\/JCO.2017.77.4414","volume":"36","author":"DL Hershman","year":"2018","unstructured":"\u2022\u2022 Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. JCO. 2018;36(26):2710\u20137. (Large scale study ultimately recognizing the impact of baseline cardiovascular risk factors on development of cardiotoxicity.)","journal-title":"JCO"},{"issue":"4","key":"590_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jchf.2019.01.002","volume":"7","author":"G Tini","year":"2019","unstructured":"Tini G, Sarocchi M, Ameri P, Arboscello E, Spallarossa P. The need for cardiovascular risk factor prevention in cardio-oncology. JACC Heart Fail. 2019;7(4):367\u20138.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"590_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaccao.2019.09.001","volume":"1","author":"AB Yin","year":"2019","unstructured":"Yin AB, Brewster AM, Barac A, Thoman W, Oeffinger KC, Gilchrist SC. Cardiovascular prevention strategies in breast cancer. JACC CardioOncology. 2019;1(2):322\u20135.","journal-title":"JACC CardioOncology"},{"issue":"20","key":"590_CR14","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441\u20137.","journal-title":"JAMA"},{"issue":"3","key":"590_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","volume":"5","author":"JM Unger","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5(3):326\u201333.","journal-title":"JAMA Oncol"},{"issue":"6","key":"590_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/HJH.0000000000002379","volume":"38","author":"A Battistoni","year":"2020","unstructured":"Battistoni A, Tocci G, Coluccia R, Burnier M, Ruilope LM, Volpe M. Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. J Hypertens. 2020;38(6):1005\u201315.","journal-title":"J Hypertens"},{"issue":"281","key":"590_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijcard.2019.01.082","volume":"15","author":"G Tini","year":"2019","unstructured":"Tini G, Sarocchi M, Tocci G, Arboscello E, Ghigliotti G, Novo G, et al. Arterial hypertension in cancer: the elephant in the room. Int J Cardiol. 2019;15(281):133\u20139.","journal-title":"Int J Cardiol"},{"issue":"33","key":"590_CR18","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"3","key":"590_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/HJH.0000000000002277","volume":"38","author":"F Liu","year":"2020","unstructured":"Liu F, Hidru TH, Gao R, Lin Y, Liu Y, Fang F, et al. Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities. J Hypertens. 2020;38(3):426\u201333.","journal-title":"J Hypertens"},{"issue":"7","key":"590_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/cncr.32690","volume":"126","author":"DL Hershman","year":"2020","unstructured":"\u2022\u2022 Hershman DL, Accordino MK, Shen S, Buono D, Crew KD, Kalinsky K, et al. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 2020;126(7):1541\u20139. (Large scale study recognizing the importance of adequate control of cardiovascular risk factors before and during cancer treatment, as nonadherence to cardiovascular medications is associated with development of cardiotoxicity.)","journal-title":"Cancer"},{"issue":"5","key":"590_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807\u201315.","journal-title":"Ann Oncol"},{"key":"590_CR22","first-page":"204748732092305","volume":"6","author":"G Tini","year":"2020","unstructured":"\u2022\u2022 Tini G, Sarocchi M, Sirello D, Murialdo R, Fornarini G, Buzzatti G, et al. Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program. Eur J PrevCardiolog. 2020;6:204748732092305. (Small real-world study showing that reaching an adequate blood pressure control before initiation of anti-VEGF agents therapy makes arterial hypertension no longer associated with cardiotoxicity.)","journal-title":"Eur J PrevCardiolog"},{"key":"590_CR23","doi-asserted-by":"publisher","first-page":"175883401774581","DOI":"10.1177\/1758834017745819","volume":"10","author":"A Cavo","year":"2018","unstructured":"Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, et al. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol. 2018;10:1758834017745819.","journal-title":"Ther Adv Med Oncol"},{"key":"590_CR24","doi-asserted-by":"crossref","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation [Internet]. 2018 Feb 20 [cited 2020 Jul 12];137(8). Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000556.","DOI":"10.1161\/CIR.0000000000000556"},{"issue":"2","key":"590_CR25","first-page":"27","volume":"10","author":"O Lanza","year":"2022","unstructured":"Lanza O, Ferrera A, Reale S, Solfanelli G, Petrungaro M, TiniMelato G, et al. New insights on the toxicity on heart and vessels of breast cancer therapies. Med Sci (Basel). 2022;10(2):27.","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"590_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","volume":"123","author":"MH Drazner","year":"2011","unstructured":"Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327\u201334.","journal-title":"Circulation"},{"issue":"6","key":"590_CR27","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/HJH.0b013e3283525715","volume":"30","author":"M Volpe","year":"2012","unstructured":"\u2022\u2022 Volpe M, Battistoni A, Tocci G, Rosei EA, Catapano AL, Coppo R, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens. 2012;30(6):1056\u201364. (Description of the importance of arterial hypertension mediated organ damage recognition to adequately assess individual cardiovascular risk profile.)","journal-title":"J Hypertens"},{"key":"590_CR28","doi-asserted-by":"crossref","unstructured":"Piskorz D. Hypertensive mediated organ damage and hypertension management. How to assess beneficial effects of antihypertensive treatments? High Blood Press Cardiovasc Prev. 2020;27(1):9\u201317.","DOI":"10.1007\/s40292-020-00361-6"},{"issue":"4","key":"590_CR29","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/HJH.0b013e328336ed09","volume":"28","author":"F Viazzi","year":"2010","unstructured":"Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M, et al. Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. J Hypertens. 2010;28(4):848\u201355.","journal-title":"J Hypertens"},{"issue":"2","key":"590_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/HJH.0b013e3283326718","volume":"28","author":"S Sciarretta","year":"2010","unstructured":"Sciarretta S, Valenti V, Tocci G, Pontremoli R, Rosei EA, Ambrosioni E, et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-developing education and awareness on microalbuminuria in patients with hypertensive disease study. J Hypertens. 2010;28(2):251\u20138.","journal-title":"J Hypertens"},{"key":"590_CR31","doi-asserted-by":"crossref","unstructured":"Tocci G, Figliuzzi I, Presta V, Attalla El Halabieh N, Citoni B, Coluccia R, et al. Adding markers of organ damage to risk score models improves cardiovascular risk assessment: prospective analysis of a large cohort of adult outpatients. Int J Cardiol. 2017;248:342\u20138.","DOI":"10.1016\/j.ijcard.2017.07.078"},{"issue":"3","key":"590_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40292-018-0265-0","volume":"25","author":"ML Muiesan","year":"2018","unstructured":"Muiesan ML, Paini A, Aggiusti C, Bertacchini F, Rosei CA, Salvetti M. Hypertension and organ damage in women. High Blood Press Cardiovasc Prev. 2018;25(3):245\u201352.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"3","key":"590_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/HYPERTENSIONAHA.121.18502","volume":"79","author":"RS Vasan","year":"2022","unstructured":"\u2022\u2022 Vasan RS, Song RJ, Xanthakis V, Beiser A, DeCarli C, Mitchell GF, et al. Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community. Hypertension. 2022;79(3):505\u201315. (Contemporary description of prevalence and significance of arterial hypertension mediated organ damage: for each blood pressure category, the presence of organ damage significantly increase cardiovascular risk.)","journal-title":"Hypertension"},{"issue":"5","key":"590_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/cancers11050622","volume":"11","author":"G Bruno","year":"2019","unstructured":"Bruno G, Bringhen S, Maffei I, Iannaccone A, Crea T, Ravera A, et al. Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy. Cancers. 2019;11(5):622.","journal-title":"Cancers"},{"key":"590_CR35","doi-asserted-by":"crossref","unstructured":"Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. npj Precision Onc. 2018;2(1):1\u201311.","DOI":"10.1038\/s41698-018-0056-z"},{"issue":"5","key":"590_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30(5):534\u201343.","journal-title":"Can J Cardiol"},{"issue":"2","key":"590_CR37","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2):e1-8.","journal-title":"Hypertension"},{"issue":"4","key":"590_CR38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","volume":"71","author":"KB Neves","year":"2018","unstructured":"Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M, et al. VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension. 2018;71(4):638\u201347.","journal-title":"Hypertension"},{"issue":"8","key":"590_CR39","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/jcm10081647","volume":"10","author":"M Bohdan","year":"2021","unstructured":"Bohdan M, Kowalczys A, Mickiewicz A, Grucha\u0142a M, Lewicka E. Cancer therapy-related cardiovascular complications in clinical practice: current perspectives. JCM. 2021;10(8):1647.","journal-title":"JCM"},{"issue":"Suppl 1","key":"590_CR40","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2459\/JCM.0000000000000377","volume":"17","author":"N Maurea","year":"2016","unstructured":"Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1):S19-26.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"16","key":"590_CR41","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.2011.40.4012","volume":"30","author":"RM Witteles","year":"2012","unstructured":"Witteles RM, Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned? JCO. 2012;30(16):1916\u20138.","journal-title":"JCO"},{"issue":"2","key":"590_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","volume":"11","author":"M Schmidinger","year":"2013","unstructured":"Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. Eur J Cancer Suppl. 2013;11(2):172\u201391.","journal-title":"Eur J Cancer Suppl"},{"issue":"2","key":"590_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OPR Hamnvik","year":"2015","unstructured":"Hamnvik OPR, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway: hypertension with anti-VEGF therapies. Cancer. 2015;121(2):311\u20139.","journal-title":"Cancer"},{"issue":"6","key":"590_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409\u201325.","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"590_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40292-017-0198-z","volume":"24","author":"D Rizzoni","year":"2017","unstructured":"Rizzoni D, De Ciuceis C, Porteri E, Agabiti-Rosei C, Agabiti-Rosei E. Use of antihypertensive drugs in neoplastic patients. High Blood Press Cardiovasc Prev. 2017;24(2):127\u201332.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"3","key":"590_CR46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","volume":"70","author":"BC Boursiquot","year":"2017","unstructured":"Boursiquot BC, Zabor EC, Glezerman IG, Jaimes EA. Hypertension and VEGF (vascular endothelial growth factor) receptor tyrosine kinase inhibition: effects on renal function. Hypertension. 2017;70(3):552\u20138.","journal-title":"Hypertension"},{"issue":"4","key":"590_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404.","journal-title":"Blood"},{"issue":"1","key":"590_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","volume":"16","author":"H Haguet","year":"2017","unstructured":"Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16(1):5\u201312.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"590_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01221-z","volume":"15","author":"JL Januzzi","year":"2022","unstructured":"Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022;15(1):1.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"590_CR50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","volume":"38","author":"A Iurlo","year":"2018","unstructured":"Iurlo A, Cattaneo D, Orofino N, Bucelli C, Molica M, Breccia M. Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option. Clin Drug Investig. 2018;38(5):475\u20136.","journal-title":"Clin Drug Investig"},{"key":"590_CR51","doi-asserted-by":"crossref","unstructured":"Cortes JE, Lomaia E, Turkina A, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses. JCO. 2020;38(15_suppl):7502\u20137502.","DOI":"10.1200\/JCO.2020.38.15_suppl.7502"},{"issue":"4","key":"590_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemiapatients candidate to ponatinib: an expert opinion. Ann Hematol. 2017;96(4):549\u201358.","journal-title":"Ann Hematol"},{"issue":"11","key":"590_CR53","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"\u2022\u2022 Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360. (European Society of Cardiology Heart Failure Association and International Cardio-Oncology Society joint position statement highlighting the importance of a baseline Cardio-Oncology evaluation before specific anticancer treatments are initiated to effectively assess cardiovascular risk and initiate strategies to prevent cardiotoxicity.)","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"590_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1021\/tx9003424","volume":"23","author":"P Menna","year":"2010","unstructured":"Menna P, Salvatorelli E, Minotti G. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival. Chem Res Toxicol. 2010;23(1):6\u201310.","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"590_CR55","doi-asserted-by":"publisher","first-page":"29994","DOI":"10.1038\/srep29994","volume":"21","author":"E Lazzarini","year":"2016","unstructured":"Lazzarini E, Balbi C, Altieri P, Pfeffer U, Gambini E, Canepa M, et al. The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. Sci Rep. 2016;21(6):29994.","journal-title":"Sci Rep"},{"issue":"6","key":"590_CR56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","volume":"22","author":"V Mercurio","year":"2016","unstructured":"Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22(6):449\u201358.","journal-title":"J Card Fail"},{"issue":"sup1","key":"590_CR57","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","volume":"11","author":"P Menna","year":"2012","unstructured":"Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11(sup1):S21-36.","journal-title":"Expert Opin Drug Saf"},{"key":"590_CR58","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.2459\/JCM.0000000000000378","volume":"17","author":"D Mele","year":"2016","unstructured":"Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, et al. Pathophysiology of anthracycline cardiotoxicity. J Cardiovasc Med. 2016;17:e3.","journal-title":"J Cardiovasc Med"},{"issue":"4","key":"590_CR59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2217\/FCA.15.35","volume":"11","author":"E Salvatorelli","year":"2015","unstructured":"Salvatorelli E, Menna P, Minotti G. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiol. 2015;11(4):363\u20136.","journal-title":"Future Cardiol"},{"issue":"25","key":"590_CR60","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. JCO. 2007;25(25):3808\u201315.","journal-title":"JCO"},{"issue":"11","key":"590_CR61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","volume":"8","author":"S Szmit","year":"2014","unstructured":"Szmit S, Jurczak W, Zaucha JM, Drozd-Soko\u0142owska J, Spycha\u0142owicz W, Joks M, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am Soc Hypertens. 2014;8(11):791\u20139.","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"590_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jhh.2014.36","volume":"29","author":"W Nadruz","year":"2015","unstructured":"Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29(1):1\u20136.","journal-title":"J Hum Hypertens"},{"issue":"17","key":"590_CR63","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","volume":"70","author":"GA Lewis","year":"2017","unstructured":"Lewis GA, Schelbert EB, Williams SG, Cunnington C, Ahmed F, McDonagh TA, et al. Biological phenotypes of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;70(17):2186\u2013200.","journal-title":"J Am Coll Cardiol"},{"issue":"323","key":"590_CR64","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijcard.2020.08.019","volume":"15","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Tanaka H, Hatazawa K, Yamashita K, Sumimoto K, Shono A, et al. Impact of hypertension on left ventricular function in patients after anthracycline chemotherapy for malignant lymphoma. Int J Cardiol. 2021;15(323):126\u201332.","journal-title":"Int J Cardiol"},{"key":"590_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2018.04.003","volume":"97","author":"G Minotti","year":"2018","unstructured":"Minotti G. The International Cardioncology Society-ONE trial: not all that glitters is for cardioncologists only. Eur J Cancer. 2018;97:27\u20139.","journal-title":"Eur J Cancer"},{"issue":"137","key":"590_CR66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.amjcard.2020.09.030","volume":"15","author":"M Hussain","year":"2020","unstructured":"Hussain M, Hou Y, Watson C, Moudgil R, Shah C, Abraham J, et al. Temporal trends of cardiac outcomes and impact on survival in patients with cancer. Am J Cardiol. 2020;15(137):118\u201324.","journal-title":"Am J Cardiol"},{"issue":"3","key":"590_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djz108","volume":"112","author":"Y Chen","year":"2020","unstructured":"Chen Y, Chow EJ, Oeffinger KC, Border WL, Leisenring WM, Meacham LR, et al. Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors. J Natl Cancer Inst. 2020;112(3):256\u201365.","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"590_CR68","first-page":"01876","volume":"S0167\u20135273","author":"G Tini","year":"2021","unstructured":"Tini G, Cuomo A, Battistoni A, Sarocchi M, Mercurio V, Ameri P, et al. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: the HFA\/ICOS risk tool in real-world practice. Int J Cardiol. 2021;S0167\u20135273(21):01876\u201383.","journal-title":"Int J Cardiol"},{"issue":"41","key":"590_CR69","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"\u2022\u2022 Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. (Recently published European Society of Cardiology guidelines on Cardio-Oncology. The paper highlights the importance of CV risk stratification in all oncologic patients before initiation of anticancer treatments and recommend adequate and aggressive control of CV risk factors in primary prevention in the oncologic population.)","journal-title":"Eur Heart J"},{"issue":"288","key":"590_CR70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijcard.2019.03.042","volume":"01","author":"G Tini","year":"2019","unstructured":"Tini G, Spallarossa P. How cardio-oncology is called to prove its maturity. Int J Cardiol. 2019;01(288):130\u20131.","journal-title":"Int J Cardiol"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-023-00590-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T09:30:57Z","timestamp":1677663057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-023-00590-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s11897-023-00590-5","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"type":"print","value":"1546-9530"},{"type":"electronic","value":"1546-9549"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"30 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}